Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 281

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 2
Chunk 281
---
 2025 compared to the six months ended June 30, 2024 was due to increased volume associated with PYRUKYND®.

Total Operating ExpensesThree Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Operating expenses:Cost of sales$1,702 $1,495 $2,787 $2,122 Research and development91,940 77,401 164,683 146,021 Selling, general and administrative45,869 35,536 87,396 66,550 Total operating expenses$139,511 $114,432 $254,866 $214,693 

Total Operating Expenses -  Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2024 – The increase in total operating expenses of $25.1 million for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily due to an increase in research and development expenses of $14.5 million, which is described below under Research and Development Expenses, and an increase in selling, general and administrative expenses of $10.3 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia.

Total Operating Expenses -  Six Months Ended June 30, 2025 vs. Six Months Ended June 30, 2024 – The increase in total operating expenses of $40.2 million for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was primarily due to an increase in selling, general and administrative expenses of $20.8 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia, and an increase in research and development expenses of $18.7 million which is described below under Research and Development Expenses.

Research and Development Expenses

Our research and development expenses, by major program, are outlined in the table below:Three Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024PK activator (PYRUKYND®)$29,809 $27,968 $51,130 $54,004 Novel PK activator (tebapivat